5 Most Promising Biotech Stocks to Buy Now

4. Insmed Incorporated (NASDAQ:INSM)

On May 7, Insmed Incorporated (NASDAQ:INSM) reported first-quarter 2026 financials. The company posted a total revenue of $306.0 million because of BRINSUPRI generating $207.9 million and ARIKAYCE contributing $98.1 million. BRINSUPRI revenue surged 44% sequentially from Q4 2025, while ARIKAYCE rose 6% YoY, showing international expansion.

Will Lewis, CEO, said in the release that commercial momentum and pipeline progress continued to build, spotlighting BRINSUPRI’s launch path and ENCORE data strength. Insmed Incorporated (NASDAQ:INSM) also stated that the study fulfilled its primary and all multiplicity-controlled secondary goals. It prepared ARIKAYCE for an SNDAs filing with the FDA in the second half of 2026.

Guidance remained solid. The company reiterated its forecasts for BRINSUPRI revenue of at least $1 billion in 2026 and ARIKAYCE sales of $450 million to $470 million. It also launched the Phase 3 PALM-PAH study of TPIP in April, adding to its late-stage pipeline.

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical company that produces and markets medicines for rare diseases. It focuses on the Brensocatib and Treprostinil Palmitil Inhalation Powder pipelines.